Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Viridian Therapeutics, Inc.\DE
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 21.79 · gapped above the open, then crossed back over prior close. High/low 22.39 at 8:15 am ET, 21.44 at 10:45 am ET.
Viridian Therapeutics, Inc.\DE has 6 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Viridian Therapeutics, Inc.\DE’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We currently rely on a single multi-site CDMO for manufacturing our clinical materials, WuXi Biologics (Hong Kong) Limited ("WuXi"), although other avenues remain available if our current manufacturer were to be negatively impacted.”
FILING10-K0001590750-26-000007cik 0001590750
“In May 2022, the Company entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma to manufacture and supply, or to have manufactured and supplied, clinical drug product for developmental purposes.”
FILING10-K0001590750-26-000007cik 0001590750
“In July 2025, we entered into a Collaboration and License Agreement pursuant to which we granted to Kissei an exclusive license to develop and commercialize products containing veligrotug and elegrobart including for the treatment of TED, in Japan, and, under certain circumstances, a non-exclusive license to manufacture such licensed products worldwide for use in Japan.”
FILING10-K0001590750-26-000007cik 0001590750
“In October 2025, we entered into a Purchase and Sale Agreement of revenue participation right (the "DRI Purchase and Sale Agreement") with DRI Healthcare Acquisitions LP ("DRI"), pursuant to which DRI purchased rights to certain revenue streams in the U.S. from us in exchange for up to $300.0 million in consideration, including $55.0 million paid at signing and conditional payments consisting of: (i) $25.0 million that is payable following the achievement of certain milestones with respect to our elegrobart pivotal phase 3 clinical trials, REVEAL-1 and REVEAL-2, on or before a specified date; (ii) $75.0 million that is payable following receipt of marketing approval for veligrotug from the FDA on or before a specified date; (iii) $15.0 million that is payable if the events set forth in the foregoing clauses (1) and (2) are met; (iv) $50.0 million that is payable following receipt of marketing approval for elegrobart from the FDA on or before a specified date; (v) at our election, $50.0 million that is payable following our achievement of net sales of certain products equal to or exceeding $1.1 billion on or before a specified date; and (vi) an additional $30.0 million that may be payable to us at a time and pursuant to financial terms agreed upon by us and DRI at such time.”
FILING10-K0001590750-26-000007cik 0001590750
“We have an exclusive license to the worldwide rights to develop and commercialize veligrotug for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of patients with TED, from ImmunoGen, Inc. ("ImmunoGen").”
FILING10-K0001590750-26-000007cik 0001590750
“In September 2022, we entered into the September 2022 ATM Agreement with Jefferies pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $175.0 million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as the sales agent.”
FILING10-K0001590750-26-000007cik 0001590750
“In July 2025, we entered into a Collaboration and License Agreement with Kissei (the "Kissei Agreement"), pursuant to which we granted to Kissei an exclusive license to develop and commercialize products containing veligrotug and elegrobart for potential treatments, including treatment of TED, in Japan, and a non-exclusive license to manufacture such licensed products worldwide for use in Japan under certain limited circumstances.”
FILING10-K0001590750-26-000007cik 0001590750
“Under the terms of the Zenas Agreements, we granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China.”
FILING10-K0001590750-26-000007cik 0001590750
“Under the terms of the Paragon Research Agreement, Paragon will perform certain development activities in accordance with an agreed upon research plan, and we will pay Paragon agreed upon development fees in exchange for Paragon's commitment of the necessary personnel and resources to perform these activities.”
FILING10-K0001590750-26-000007cik 0001590750
“In January 2025, Zenas BioPharma sublicensed their rights under the license agreement to Zai Lab and assigned the Manufacturing Development and Supply Agreement to Zai Lab in connection with the sublicense transaction.”
FILING10-K0001590750-26-000007cik 0001590750
“In August 2025, the Company entered into a material transfer agreement ("MTA") with Zai Lab, to supply certain materials for clinical trial use.”
FILING10-K0001590750-26-000007cik 0001590750
Watchlist prices, news filtered to it, and its next report on your desk.
VRDN (Viridian Therapeutics, Inc.\DE) has 6 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ZLAB +1.02%, in industrials & materials.